Blueprint Medicines, headquartered in Cambridge, Massachusetts, develops precision therapies for cancer and blood disorders, employing 645 fulltime staff. It has approved medicines like AYVAKIT and GAVRETO, with ongoing research in various cancers.
Ariel Hurley sold 2,752 shares of BPMC on 5 May at $104.78 per share, worth a total of $288K. They now own 18,444 BPMC shares, or a 14% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
